CY1118518T1 - Αναστολεις της κινασης p38 μαp - Google Patents

Αναστολεις της κινασης p38 μαp

Info

Publication number
CY1118518T1
CY1118518T1 CY20171100002T CY171100002T CY1118518T1 CY 1118518 T1 CY1118518 T1 CY 1118518T1 CY 20171100002 T CY20171100002 T CY 20171100002T CY 171100002 T CY171100002 T CY 171100002T CY 1118518 T1 CY1118518 T1 CY 1118518T1
Authority
CY
Cyprus
Prior art keywords
optionally substituted
hydrogen
group
radical
inhibitors
Prior art date
Application number
CY20171100002T
Other languages
Greek (el)
English (en)
Inventor
David Charles Festus Moffat
Stéphane Pintat
Stephen Davies
Original Assignee
Chroma Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608855A external-priority patent/GB0608855D0/en
Priority claimed from GB0613914A external-priority patent/GB0613914D0/en
Application filed by Chroma Therapeutics Limited filed Critical Chroma Therapeutics Limited
Publication of CY1118518T1 publication Critical patent/CY1118518T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20171100002T 2006-05-04 2017-01-02 Αναστολεις της κινασης p38 μαp CY1118518T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0608855A GB0608855D0 (en) 2006-05-04 2006-05-04 Inhibitors of MAP kinase enzymes
GB0613914A GB0613914D0 (en) 2006-07-13 2006-07-13 Inhibitors of p38 map kinase
PCT/GB2007/001596 WO2007129040A1 (en) 2006-05-04 2007-05-01 p38 MAP KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
CY1118518T1 true CY1118518T1 (el) 2017-07-12

Family

ID=38268953

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100002T CY1118518T1 (el) 2006-05-04 2017-01-02 Αναστολεις της κινασης p38 μαp

Country Status (15)

Country Link
US (1) US8044211B2 (enExample)
EP (1) EP2013175B9 (enExample)
JP (1) JP5340918B2 (enExample)
KR (1) KR101429780B1 (enExample)
CN (1) CN102942520B (enExample)
AU (1) AU2007246869B2 (enExample)
BR (1) BRPI0711310B8 (enExample)
CA (1) CA2650970C (enExample)
CY (1) CY1118518T1 (enExample)
DK (1) DK2013175T5 (enExample)
ES (1) ES2605727T3 (enExample)
HU (1) HUE033281T2 (enExample)
NZ (1) NZ573348A (enExample)
PT (1) PT2013175T (enExample)
WO (1) WO2007129040A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) * 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
CA2668070A1 (en) * 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
UA98961C2 (uk) 2007-06-27 2012-07-10 Астразенека Аб Похідні піразинону та їх застосування у лікуванні легеневих захворювань
WO2009060160A1 (en) * 2007-11-07 2009-05-14 Chroma Therapeutics Ltd. P38 map kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
ES2427892T3 (es) * 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
SI3222616T1 (sl) 2012-10-17 2019-10-30 Macrophage Pharma Ltd N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester
GB201306901D0 (en) * 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163957A0 (en) * 2002-03-14 2005-12-18 Bayer Healthcare Ag Monocyclic aroylpyridinones as antiinflammatory agents
MX2007013257A (es) * 2005-05-05 2008-01-21 Chroma Therapeutics Ltd Conjugados de ester de alfa-aminoacido-farmaco hidrolizables por carboxilesterasa.
ES2427892T3 (es) * 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38

Also Published As

Publication number Publication date
CA2650970A1 (en) 2007-11-15
BRPI0711310B8 (pt) 2021-05-25
WO2007129040A1 (en) 2007-11-15
BRPI0711310A2 (pt) 2011-12-06
EP2013175B9 (en) 2020-11-11
NZ573348A (en) 2012-01-12
ES2605727T9 (es) 2020-12-11
DK2013175T5 (da) 2020-12-21
AU2007246869A1 (en) 2007-11-15
HUE033281T2 (en) 2017-11-28
US8044211B2 (en) 2011-10-25
AU2007246869B2 (en) 2012-10-18
EP2013175B1 (en) 2016-11-09
PT2013175T (pt) 2017-02-14
CA2650970C (en) 2014-09-16
KR101429780B1 (ko) 2014-08-18
KR20090014187A (ko) 2009-02-06
US20090099185A1 (en) 2009-04-16
ES2605727T3 (es) 2017-03-16
CN102942520A (zh) 2013-02-27
EP2013175A1 (en) 2009-01-14
JP5340918B2 (ja) 2013-11-13
DK2013175T3 (en) 2017-02-20
JP2009535385A (ja) 2009-10-01
CN102942520B (zh) 2015-03-04
BRPI0711310B1 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
BRPI0711310B8 (pt) composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
EA200500875A1 (ru) Производные 3-аминопирролидина в качестве модуляторов рецепторов хемокинов
CY1111706T1 (el) Παραγωγα αρυλο- και ετεροαρυλο-πιπεριδινοκαρβοξυλικων αλατων, η παρασκευη τους και η εφαρμογη τους ως αναστολεις του ενζυμου faah
NO965521D0 (no) N-substituert-(dihydroksyboryl)alkylpurin-, -indol- og -pyrimidinderivater som kan anvendes som inhibitorer for inflammatoriske cytokiner
DK1696919T3 (da) 3-cycloalkylaminopyrrolidin-derivater som modulatorer af chemokinreceptorer
IS8056A (is) Bensoxasínýl-amídósýklópentýl-heterósýklýskir stillar á flakkboða viðtaka
ES2271615T3 (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados y su uso como antibacterianos.
CY1116610T1 (el) Ετεροδιμερη γλουτamiνiκου οξεος
CY1112011T1 (el) Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
EA201001280A1 (ru) Селекция организмов, способных сбраживать смешанные субстраты
AR075084A1 (es) Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
EA200300777A1 (ru) N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов для fsad
PH12013501196B1 (en) Indeno- fused ring compounds having photochromic properties
MX2009004442A (es) Inhibidores de la proteina cinasa de serina-treonina ikk-beta.
DE602005025383D1 (de) Verwendung von pyrrolo-pyrazinderivaten zur behandlung der zystischen fibrose
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20121152A1 (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
ATE421574T1 (de) Zellkulturmethode zur erzeugung von prostata- ähnlichen acini
GB0903480D0 (en) Enzyme Inhibitors
ATE540051T1 (de) Age-inhibitoren
ATE488252T1 (de) Erhöhte transduktion mit abc- transportersubstratenhemmern
BR0008589A (pt) Composto de tipirano, processo para sua preparação e seu uso
ATE540313T1 (de) Identifizierung von keimbahnfähigen embryonischen stammzellen
CY1119080T1 (el) Ν-[2-{4-[6-αμινο-5-(2,4-διφθοροβενζοϋλ)-2-οξοπυριδιν-1(2η)-υλ]-3,5-διφθοροφαινυλ}αιθυλ]-l-αλανιnικο tert-boytyλio ή ενα αλας, υδριτης ή διαλυτωμα αυτου